1. ALT/AST > 5 times the upper limit of normal. 2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) 3. Pregnancy or breast feeding. 4. Allergy to any study medication 5. Any medical condition which would impose an unacceptable safety hazard by participation to the study. 6. Study drug specific exclusion criteria: - for itraconazole: heart failure , concomitant treatment with lopinavir/ritonavir, and potent CYP450 inducers such as rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin.

1. ALT/AST > 5 times the upper limit of normal. 2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) 3. Pregnancy or breast feeding. 4. Allergy to any study medication 5. Any medical condition which would impose an unacceptable safety hazard by participation to the study. 6. Study drug specific exclusion criteria: - for itraconazole: heart failure , concomitant treatment with lopinavir/ritonavir, and potent CYP450 inducers such as rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin.